News Daily News ‘Call to Action’ in India, Where Hypertension and Diabetes Loom Large Michael O'Riordan January 30, 2018
News Daily News Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers Yael L. Maxwell January 24, 2018
News Daily News Synopsis of New Hypertension Guidelines Renews Concerns and Controversy L.A. McKeown January 22, 2018
News Daily News Low Rate of Bailout Emergency Surgery During TAVR, but Caution Still Needed Michael O'Riordan January 10, 2018
News Daily News Sex Differences Diminish With Third-Generation TAVR Device L.A. McKeown January 05, 2018
News Daily News Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond Shelley Wood December 26, 2017
News Daily News Some Concerns About New ‘Tour de Force’ Hypertension Guidelines Todd Neale December 04, 2017
News Conference News AHA 2017 More Support for TMVR After Failed Mitral Bioprostheses Yael L. Maxwell November 23, 2017
News Opinion Editor's Corner TCT 2017 My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self Shelley Wood November 22, 2017
News Conference News AHA 2017 Long-Awaited Hypertension Guidelines Released at AHA Todd Neale November 13, 2017
News Conference News TCT 2017 Experts Debate: Should Cerebral Protection Be Used for All TAVRs? Todd Neale November 09, 2017
News Conference News TCT 2017 A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients Todd Neale November 08, 2017
Presentation TCT 2017 Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER Presenter: Pamela S. Douglas November 01, 2017
News Conference News TCT 2017 Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery Yael L. Maxwell October 31, 2017
Presentation TCT 2017 PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis Presenter: Patrick W. Serruys, David J. Cohen October 31, 2017
Presentation TCT 2017 Important Clinical Lessons From the VIVID Registry and the PARTNER Experience Presenter: John G. Webb October 30, 2017
Presentation TCT 2017 Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients Presenter: Michael J. Reardon October 30, 2017
Presentation TCT 2017 Clinical Case #3 Presenter: Anibal A. Damonte, Alejandro O. Palacios, Alfredo E. Rodriguez October 29, 2017